11 results about "Corpus callosum" patented technology

[Problem] Conventionally, it has not been possible to simulate brain activity when performing an operation with consideration for long-term memory and short-term memory. [Solution] The problem can be solved by an information processing device 1 comprising: a reception unit 12 that receives information; a feature acquisition unit 131 that acquires a feature set from the information; a transfer unit 132 that performs a transfer process for determining one or more node identifiers paired with a start point condition which matches the feature set and determining a firing node identifier of a node to be fired, which is connected by an edge to a fired node that is identified by each of one or more node identifiers; and a corpus callosum unit 133 that acquires a long-term firing pattern and a short-term firing pattern from one or more firing node identifiers which have been determined by the transfer unit 132, determines, from among an operation paired with a firing pattern that is similar to the long-term firing pattern and an operation paired with a firing pattern that is similar to the short-term firing pattern, an operation which matches an operation condition, and performs the determined operation.

An automatic calculation method of gray-to-white-matter ratio for head computed tomography of patients with cardiac arrest is disclosed and includes an image registration step, a K-means segmentation step, a segmentation refinement step and a GWR calculation step. Measure the gray-white-matter ratio through brain computed tomography early after cardiac arrest to automatically identify the corpus callosum, caudate nucleus, putamen, and posterior branch of the internal brain cyst. It is a 3D three-dimensional structure rather than a manually selected flat circular area to evaluate the effectiveness of predicting neurological prognosis at discharge.

The invention provides application of a salidroside derivative in preparation of a medicine for preventing and / or treating cognitive impairment caused by cerebrovascular lesion, and belongs to the technical field of biological medicine. The invention discloses application of a salidroside derivative SHPL-49 in preparation of a medicine for preventing and / or treating cognitive impairment caused by cerebrovascular lesion. The SHPL-49 can effectively improve the learning and memory functions after brain injury, recover the exercise coordination ability, relieve corpus callosum region myelin sheath loss above the hippocampus region and further protect the brain-sea horse region synapses. The SHPL-49 has the efficacy of treating the vascular cognitive impairment and the vascular dementia. According to the application, the medical application of the SHPL-49 is widened, and a new way is provided for treating cognitive impairment diseases caused by cerebrovascular lesion.

Abnormal activity in the brain can be detected by identifying changes in tissue excitability measured in response to stimulation of fiber tracts such as the corpus callosum. A stimulating electrode contact can apply a stimulation to the fiber tract, which can have one or more terminals to a cortex of a patient's brain, and a recording electrode contact positioned in the fiber tract and / or the cortex to record a tissue excitability response to the stimulation. A controller can receive the tissue excitability response from the at least one recording electrode, identify a parameter of the tissue excitability response, and predict the abnormal activity in the patient's brain based on the parameter being different from a baseline for the parameter. When an abnormal activity is predicted the patient can be alerted to start a therapy and / or a therapy can be applied in closed loop manner by a connected therapy device.

The invention discloses a construction method and application of a prediction model for primary corpus callosum-related pneumonia, and the construction method comprises the following steps: obtaining clinical data and laboratory test results of patients with primary corpus callosum degeneration; carrying out single-factor analysis and screening related factors having statistical significance with the primary corpus callosum degeneration-related pneumonia; the method comprises the following steps: carrying out dimensionality reduction treatment on related factors with statistical significance of primary corpus callosum degeneration-related pneumonia, and carrying out multi-factor logistic regression analysis on the related factors subjected to dimensionality reduction treatment to determine independent related factors of primary corpus callosum degeneration-related pneumonia; and according to the independent related factors of the primary corpus callosum degeneration-related pneumonia, constructing a prediction model of the primary corpus callosum degeneration-related pneumonia. The prediction model constructed by the invention has good prediction capability, and clinicians can identify high-risk patients with primary corpus callosum degeneration related pneumonia as soon as possible and perform intervention and treatment as soon as possible.

[Problem] It has not been possible to simulate the mechanism of memory in the brain. [Solution] The mechanism of memory in the brain can be simulated by an information processing device 1 comprising: a hippocampus unit 114 that stores one or more firing patterns; a transmission unit 131 that is connected to nodes identified by one or more node identifiers of one or more firing nodes corresponding respectively to the one or more firing patterns in the hippocampus unit 114, and determines which node to fire; a positive amygdala unit 133 that obtains a degree of positivity using the number of firing nodes of the positive amygdala; a negative amygdala unit 134 that obtains a degree of negativity using the number of firing nodes of the negative amygdala; and a corpus callosum unit 132 that obtains a firing pattern in which the firing state satisfies a steady-state condition, obtains a signal intensity using the degree of positivity and the degree of negativity, and accumulates long-term memory information having the firing pattern and the signal intensity in a cortex unit 113.

[Problem] To solve the problem that movement in a brain cannot be simulated when performing an operation in consideration of an expectation value in the past. [Solution] The above problem can be solved by an information processing device 1 comprising: an operation management unit 115 in which operation information associated with two or more operation identifiers is stored; a cortex unit 116 in which one or more past operation identifiers are stored in association with a feature set, which is one or more pieces of feature information, and an expected value; a reception unit 12 for receiving information; a feature acquisition unit 131 for acquiring a feature set from the received information; and a corpus callosum unit which, for one or more candidate operation identifiers among one or more past operation identifiers, acquires the similarity between the feature set associated with the candidate operation identifier and the feature set acquired by the feature acquisition unit 131, acquires a score by using the similarity and an expectation value paired with the candidate operation identifier, acquires operation information paired with one or more operation identifiers whose scores satisfy the operation condition from the operation management unit 115, and performs an operation according to the one or more pieces of operation information.

A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and / or (2) at least 5% of all of the glial cells in the white matter of the brain and / or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.

The present disclosure relates to the field of medicine, and more particularly to the use of elastase inhibitors in the preparation of medicaments for treating cerebral hypoperfusion. Studies in the disclosed examples have revealed that NE expression is elevated in the corpus callosum of patients with cerebral hypoperfusion. NE can cause damage to oligodendrocytes and white matter lesions. Elastase inhibitors can effectively inhibit NE expression and activity, reducing oligodendrocyte damage. They also mitigate the enzymatic cleavage of NE on the myelin protein CNPase, reducing myelin damage in the corpus callosum and thereby inhibiting white matter lesions.

The invention relates to the technical field of medical diagnosis, and in particular relates to a method for preparing a gene based on NOTCH3 gene c.4738Tgt; the invention discloses a method for non-invasive prenatal evaluation of fetal corpus callosum dysplasia by A mutation. The method comprises the steps of sample collection, plasma separation and free DNA extraction, primer design, targeted sequencing and analysis. Compared with traditional ultrasonic and interventional prenatal diagnosis, the method for noninvasive prenatal diagnosis of fetal corpus callosum dysplasia has the advantages that trauma is small, cost is low, feasibility and operability are high, pregnant women can accept the method easily, the risk of abortion and the like caused by invasive prenatal diagnosis is avoided, and the method is suitable for clinical application. Therefore, the couple with family history can obtain early safe prenatal diagnosis.

A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and / or (2) at least 5% of all of the glial cells in the white matter of the brain and / or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.